Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The Ma’anshan site approval covers pastilles, oral liquids, and powders
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Subscribe To Our Newsletter & Stay Updated
